IL6 and Guillain-Barre syndrome: Our data are also consistent with in vivo observations wherein IVIg treatment reduces serum IL-6 and IL-6 production by LPS-stimulated whole blood in children with Kawasaki disease, and reduces serum TNF and IL-1β levels in patients with Guillain-Barré syndrome (36, 37).